Table 1 Descriptive data.

From: The contribution of platelets to peripheral BDNF elevation in children with autism spectrum disorder

 

ASD (n = 94)

DD (n = 21)

TYP (n = 52)

n

%

n

%

n

%

Male

76

81

13

62

37

71

White

66

70

12

57

38

73

Anticonvulsant medication

9

10

3

14

0

 

Antipsychotic medication

8

9

1

5

0

 

Selective serotonin reuptake inhibitor

2

2

0

 

0

 
 

M

SD

M

SD

M

SD

Age (years)

4.91

1.59

4.91

1.49

4.27

1.65

Vineland-II composite (standard score)

64.90

8.79

71.90

9.34

103.54

9.26

Nonverbal developmental quotient

56.02

18.75

57.51

17.06

111.59

14.01

BMI Z-score

0.52

1.21

0.02

1.28

0.51

1.09

Platelet count (103/mm3)

336

79

334

66

290

46

BDNF (ng/mL)

18.14

8.16

17.28

8.19

14.18

9.84

  1. Some data were missing: BMI, n = 9 in ASD, n = 3 in DD, n = 3 in TYP. Platelets, n = 7 in TYP. Psychotropic medications, n = 3 TYP. Eighteen (19%) children in the ASD group, three (14%) in the DD group, and none of the participants in the TYP group had elevated platelets, according to age- and sex-based clinical laboratory reference ranges. Age ranges in the groups were ASD 2.01–9.21 years, DD 2.83–8.07 years, and TYP 1.25 to 7.86 years.
Back to article page